ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years

Rishika Prasad

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-6875-0954; OpenAlex author ID A5020134508. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2021: 1 paper · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 2

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Reena C. Jha · 1 shared paper, 2026 · strength 0.43
- Paper How cholecystectomy and gastrectomy contribute to pancreatic cancer development: a review. DOI 10.1097/ms9.0000000000005476 ↗
Akash R. Boda · 1 shared paper, 2021 · strength 0.11
- Paper High potency STING agonists engage unique myeloid pathways to reverse pancreatic cancer immune privilege. DOI 10.1136/jitc-2021-003246 ↗
Casey R. Ager · 1 shared paper, 2021 · strength 0.11
- Paper High potency STING agonists engage unique myeloid pathways to reverse pancreatic cancer immune privilege. DOI 10.1136/jitc-2021-003246 ↗
Michael A. Curran · 1 shared paper, 2021 · strength 0.11
- Paper High potency STING agonists engage unique myeloid pathways to reverse pancreatic cancer immune privilege. DOI 10.1136/jitc-2021-003246 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.